Transforming How Patients Manage Chronic Conditions: Waqaas Al-Siddiq, Biotricity

·26 min·1 clip

Biotricity says 87,000 people avoided a heart attack or stroke because of its product.

1. The Real Chemistry Podcast episode focuses on Waqas Al-Siddiq and Biotricity’s approach to cardiac monitoring and chronic condition management. 2. Aaron Strout, Real Chemistry’s Chief Marketing Officer, hosts the conversation, and Waqas Al-Siddiq is the CEO and founder of Biotricity, a company he says combines technology and healthcare. 3. The episode asks how Biotricity can help patients and cardiologists manage heart disease across the full care journey. 4. Al-Siddiq traces his background to graduate work on sensor networks and wireless monitoring of environments. 5. He says his technical path ran through Intel, AMD, IBM, architectural computing, cloud computing, and processors before he entered healthcare. 6. He explains that investment-advisory work in digital health and wireless applications showed him where the market was heading. 7. He says that experience created the “light bulb” moment that led him to found Biotricity. 8. Al-Siddiq says the name Biotricity comes from “biology and electricity.” 9. He says the company’s logo was developed with a design firm and is often seen as a flower tied to birth and life. 10. He says 70 cents of every dollar spent on chronic conditions goes to heart disease, which he calls the number one killer in that category. 11. He says cardiac problems are often intermittent and asymptomatic, which makes them difficult to detect. 12. He describes Biotricity’s first product as a smart diagnostic monitor designed to catch problems that might happen at 3:00 in the morning. 13. He contrasts smart diagnostics with passive diagnostics and says the company also built products for condition management after diagnosis. 14. He says physicians want only clinically relevant data, not noise from unrelated consumer wearables like Fitbit data. 15. He says Biotricity aligns its outputs with clinical pathways because pathways drive outcomes, reimbursement, and revenue. 16. He says the company received an NIH grant and is studying how cardiac data may apply to chronic kidney disease, prediction, notifications, and clinical trials. 17. He says about 87,000 people avoided a heart attack or stroke because of Biotricity’s product. 18. The interview style is conversational and technical, with Aaron Strout asking for concrete examples, payer details, and product comparisons. 19. Listeners interested in cardiac devices, digital health, and reimbursement strategy would likely want this episode. 20. Listeners looking for celebrity-style banter or light entertainment would likely skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Real Chemistry Podcast